Accordingly, the anti-TNF agents infliximab, adalimumab, and certolizumab pegol induce the apoptosis of TNFR2-expressing T cells isolated from IBD patients by binding to transmembrane TNF-α (mTNF-α)-expressing CD14+ macrophages [193]. Here, TNFRSF1B is linked to inflammatory bowel disease.